Posted by Michael Wonder on 13 Jun 2019
Amgen wins FDA approval for Kanjinti injection for treatment of breast cancer, gastro-esophageal junction adenocarcinoma
13 June 2019 - U.S. FDA says Kanjinti (trastuzumab-anns) is biosimilar to Herceptin (trastuzumab).
U.S. FDA says Kanjinti comes with a boxed warning for cardiomyopathy, infusion reactions, embryo-fetal toxicity, pulmonary toxicity.
